A Phase 2 Study of REGN2810 a Fully Human Monoclonal Antibody to Programmed Death-1 in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor therapy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Basal Cell Carcinoma
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1.  Patient must have histologically confirmed diagnosis of invasive basal cell carcinoma, with a life expectancy greater than 12 weeks

     

    2.  Patient must be deemed unlikely to benefit from further therapy with an HHI, either due to prior progression of disease on HHI therapy or intolerance of prior HHI therapy.


You may not be eligible for this study if the following are true:

  • 1.  Patients with ongoing or recent (5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments.

     

    2.  Prior treatment with an agent that blocks the PD-1/PD-L1 pathway

     

    3.  Patients with allergy or hypersensitivity to REGN2810

     

    4.  Breastfeeding or Pregnancy




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.